Bangalore, Karnataka, India, Tuesday, January 11, 2011 -- (Business Wire India) -- Biocon, Asia's leading biopharmaceutical enterprise, released preliminary data from a recently concluded clinical ...

BENGALURU, India--(BUSINESS WIRE)--Biocon Limited (BSE: 532523; NSE: BIOCON) today announced the appointment of Shreehas Tambe as its Chief Executive Officer & Managing Director, effective April 1, ...

Commenting on the quarterly performance and highlights, Chairman and Managing Director, Kiran Mazumdar-Shaw stated,"A significant ramp up in Research and Development expenses this quarter reflects ...

I would now like to hand the conference over to Ankit from Biocon Investors Relations. Thank you and over to you Ankit. Thank you, Melvin. Good morning everyone. I hope you are fine and in good health ...

Q4 Revenue from Operations: INR4,417 crore, 15% year-on-year increase, 16% sequential growth. Q4 Core EBITDA: INR1,363 crore, 16% year-on-year increase, with a core operating margin of 31%. Q4 ...

Jain also noted Emcure Pharmaceuticals is sustaining breakout levels. He recounted that the stock's initial IPO-based breakouts failed twice, however, in the third attempt, the stock gave excellent ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...